Drug Approval | July 26, 2023
NATCO files generic Erdafitinib Tablets in USA
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Good momentum in commercial CDMO business
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Advances clinical research capabilities with leading regulatory grade registries platform
Subscribe To Our Newsletter & Stay Updated
